 However, it is a strong inhibitor of the cytochrome P450 enzyme mediated metabolism and it is only used in a combination therapy with other protease inhibitors for pharmacokinetic boosting.Indinavir, which is a peptidomimetic hydroxyethylene HIV protease inhibitor, reached the market in 1996.The design of indinavir was guided by molecular modeling and the X-ray crystal structure of the inhibited enzyme complex.